Notes: October 30, 2023 -- Catalyst Biosciences, Inc. (Nasdaq: CBIO) (“Catalyst”) today announced completion of the business combination with GNI Group Ltd. and related entities. Catalyst received stockholder approval for all proposals necessary to complete the business combination at a special meeting of stockholders held on August 29, 2023. Catalyst effected a name change and a reverse stock split of Catalyst’s common stock immediately prior to the closing of the business combination. The combined company will operate under the name “Gyre Therapeutics, Inc.” (“Gyre”). As a result of the business combination, Beijing Continent Pharmaceuticals Co., Ltd. became a majority-owned subsidiary of Gyre. To ensure Gyre’s compliance with the minimum bid price requirement of $4.00 per share for initial listing on The Nasdaq Capital Market, Catalyst implemented a reverse split of its common stock at a ratio of 1-for-15 shares. In the reverse stock split, every 15 shares of Catalyst common stock outstanding was combined and reclassified into one share of Gyre common stock. <p> February 13, 2017 -- Catalyst Biosciences, Inc. (CBIO) will effect a one-for-fifteen (1-15) reverse split of its common stock. The CUSIP number will change to 14888D208.________________August 20, 2015 -- An EX date has been established for the pre-closing dividend/distribution in connection with its merger with Catalyst Biosciences, Inc., of an aggregate cash amount of $19,500,000, which is approximately $0.5686 per share, and non-interest bearing, redeemable convertible notes with an aggregate principal amount of $37,000,000, which is approximately $1.079 per share. Targacept, Inc. (TRGT) will effect a one for seven (1-7) reverse split of its outstanding common stock as well as a name, symbol, and CUSIP change. The new name will be Catalyst Biosciences, Inc. The new symbol will be CBIO. The CUSIP number will change to 14888D109. The reverse split, change of name, symbol, and CUSIP will be effective at the opening of business on Friday, August 21, 2015._______________ May 14, 2015 -- Targacept, Inc. (NASDAQ: TRGT) and Catalyst Biosciences, Inc., a privately held biopharmaceutical company, jointly announced that they have entered into an amendment to the definitive agreement to merge the two companies. The boards of directors of both companies have unanimously approved the amendment to the merger agreement. Targacept stockholders would retain common stock representing approximately 42 percent of the combined company. A 30-month period for Targacept stockholders to convert the $37 million of redeemable convertible notes into the combined company’s common stock or redeem them for cash. If the proposed merger is completed, the combined entity, to be named Catalyst Biosciences, Inc. with an anticipated listing on the NASDAQ Global Select Market under the symbol CBIO.